References. Actuate Therapeutics receives FDA orphan drug designation for elraglusib for treatment of pancreatic cancer. News release.
FDA Grants Orphan Drug Designation to Elraglusib for Pancreatic Cancer – OncLive
Share This Story, Choose Your Platform!
About the Author:
